Philip Morris International Inc (NYSE:PM) Issues Scientific Update for Smoke-Free Offerings On Clinical Program

1121

Philip Morris International Inc (NYSE:PM) issued Scientific Update publication for Smoke-Free offerings, a regular update on its research initiatives to advance and evaluate a range of smoke-free options to cigarettes.

The details

The latest publication of the Scientific Update offers a closer look at some of the practices and principles on which Philip Morris’ scientific assessment plan is made. Dr. Patrick Picavet, the Director of Medical Affairs, details specific instances from company’s clinical plan that highlight the firm’s commitment to the application of best practices, the well-being of subjects in clinical trial and transparent research.

Picavet expressed that the performance of clinical trials is a complicated procedure. Strict application of Good Clinical Practices is mainly important to assure the consistency and quality of the research and to address unanticipated events that can happen during a trial. These practices are significant to the safety of study participants and the validity of data.

Beyond recent publications and events, this concern also describes Philip Morris’ advancement towards sharing all raw information from trials on IQOS in part via the latest data-sharing platform named INTERVALS. Professor Manuel Peitsch, the CEO of Philip Morris, elaborated that the company is dedicated to sharing the research results behind their smoke-free products in an extremely transparent way. That’s why they are utilizing their latest Scientific Update to highlight the rigor behind their clinical program.

The company is going further by progressively making the results and data from the clinical and non-clinical program around their major smoke-free product named IQOS, brought to market by early 2018.

Philip Morris International’s extensive assessment and research program is supported by the well-set practices of the pharmaceutical market and at par with the draft projection of the U.S. FDA for MRTP Applications. The company engages more than 400 world-class engineers, experts and scientists who perform rigorous research.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.